Skip to main content

Advertisement

SpringerLink
Log in

The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

To investigate the efficacy and relationship between plasma concentrations at the end of infusion (C end of infusion) and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC).

Patients and methods

Patients were given gemcitabine by 120 min infusion [at a fixed dose rate (FDR) of 10 mg/m2/min] on days 1 and 8 of a 21-day cycle, immediately followed by carboplatin AUC 5 by 4 h infusion on day 1. C end of infusion of gemcitabine was determined by ion-pair reversed-phase high-performance liquid chromatography (HPLC).

Results

By the close-out date, in our study population, the estimated median time to tumor progression (TTP) was 7 months (95% CI 4–10 months), median overall survival (OS) was 12 months (95% CI 11.2–12.8 months). The mean value of C end of infusion of 21 eligible patients was 16.48 ± 8.07 μmol/l (range 27.43–2.87 μmol/l). The main hematological toxicities were transient grade 3–4 thrombocytopenia. The mean percentages of reduction of WBC, NEC, PLTC and Hb of 21 eligible patients were 38.3 ± 38.1%, 31.3 ± 73.6%, 31.8 ± 53.5% and 12.0 ± 12.2%, respectively. The analysis of the C end of infusion of gemcitabine and the percentage of reduction in WBC showed a significant correlation (r 2 = 0.4575; p < 0.05). A significant correlation (r 2 = 0.5671; p < 0.05) was also observed between the percentage of reduction of PLTC and C end of infusion of gemcitabine infusion.

Conclusion

The clinical data in this trial supports the further evaluation the regimen in advanced NSCLC patients, due to its predictable kinetic behavior and less severe toxicity profile than expected.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Hertel LW, Kroin JS, Misner JW et al (1988) Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2-difluoro-D-ribofuranosyl nucleosides. J Org Chem 53:2406–2409

    Article  CAS  Google Scholar 

  2. Yokoyama A, Nakai Y, Yoneda S et al (1997) Activity of gemcitabine in the treatment of patients with non-small-cell lung cancer: a multicenter phase study. Anti-cancer Drugs 8:574–581

    Article  PubMed  CAS  Google Scholar 

  3. Pollera CF, Ceribelli A, Crecco M et al (1994) Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase study. Ann Oncol 5:182–184

    PubMed  CAS  Google Scholar 

  4. Burris HA, Moore MJ, Anderson J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413

    PubMed  CAS  Google Scholar 

  5. Carmichael J, Possinger K, Phillip P et al (1995) Advanced breast cancer. A phase 2 trial with gemcitabine. J Clin Oncol 13:2731–2736

    PubMed  CAS  Google Scholar 

  6. Heinemann V, Hertel LW, Grindey GB et al (1988) Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 48:4024–4031

    PubMed  CAS  Google Scholar 

  7. Heinemann V, Xu Y-Z, Chubb S, et al (1990) Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 38:567–572

    PubMed  CAS  Google Scholar 

  8. Huang P, Chubb S, Hertel LW et al (1991) Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110–6117

    PubMed  CAS  Google Scholar 

  9. Huang P, Plunkett W (1995) Fludarabine and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 36:181–188

    PubMed  CAS  Google Scholar 

  10. Grunewald R, Kantarjian H, Keating MJ et al (1990) Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine(gemcitabine) administration in leukemia. Cancer Res 50:6823–6826

    PubMed  CAS  Google Scholar 

  11. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98

    Article  PubMed  CAS  Google Scholar 

  12. Sederholm C (2002) Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer study group. Semin Oncol 29:50–54

    Article  PubMed  CAS  Google Scholar 

  13. Thomas P, Robinet G, Gouva S et al (2006) Randomized multicenter phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small-cell lung cancer GFPC 1999–2001 study (Groupe francais de pneumo-cancerologie). Lung Cancer 51:105–114

    Article  PubMed  CAS  Google Scholar 

  14. Zatloukal P, Petruzelka L, Zemanova M et al (2003) Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small-cell lung cancer: a phase randomized trial. Lung Cancer 41:321–331

    Article  PubMed  Google Scholar 

  15. Manuel D, Laura GE, Ana L (2002) A phase II trial of a two hour infusion of gemcitabine with carboplatin for advanced non-small-cell lung cancer (NSCLC). Ann Oncol, 13(suppl.5):143

    Google Scholar 

  16. Schmid P, Akrivakis K, Flath B et al (1999) Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 10:625–631

    Article  PubMed  CAS  Google Scholar 

  17. Wang LR, Huang MZ, Xu N, et al (2005) Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer. J Zhejiang Univ Sci B 6:446–450

    Article  PubMed  Google Scholar 

  18. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  19. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481

    Article  Google Scholar 

  20. Eisenhauer EA, Vermorken JB (1998) The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 55:5–30

    Article  PubMed  CAS  Google Scholar 

  21. Noble S, Goa KL (1997) Gemcitabine. A review of its pharmacology and clinical potential in non-small-cell lung cancer and pancreatic cancer. Drugs 54:447–472

    Article  PubMed  CAS  Google Scholar 

  22. Fogli S, Danesi R, De Braud F et al (2001) Drug distribution and pharmacokinetic/pharmaco-dynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. Ann Oncol 12:1553–1559

    Article  PubMed  CAS  Google Scholar 

  23. Rowland M, Tozer TN (1995) (Third edition) Clinical Pharmacokinetics: Concepts and Applications. Baltimore, Williams and Wilkins, Maryland

  24. Tempero M, Plunkett W, Ruiz van H et al (2003) Randomized phase II comparison of dose-intense Gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402–3408

    Article  PubMed  CAS  Google Scholar 

  25. Domine M, Estevez L, Leon A et al (2002) Phase II trial of a two-hour infusion of gemcitabine with carboplatin for advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21:225b

    Google Scholar 

  26. Rudd RM, Gower NH, Eisen TG et al (2005) Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 23:142–153

    Article  PubMed  CAS  Google Scholar 

  27. Kroep JR, Giaccone G, Voorn DA et al (1999) Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol 17:2190

    PubMed  CAS  Google Scholar 

  28. Yonemori K, Ueno H, Okusaka T et al (2005) Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 11:2620–2624

    Article  PubMed  CAS  Google Scholar 

  29. Soo RA, Wang LZ, Tham LS et al (2006) A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Ann Oncol 17:1128–1133

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from the Medical Science Research Foundation of Zhejiang province, China (N0. 2004A028).

Author information

Authors and Affiliations

  1. Department of Pharmacy, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, People’s Republic of China

    Linrun Wang, Xiuhua Wu, Mingzhu Huang & Jie Cai

  2. Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, People’s Republic of China

    Nong Xu

  3. Department of Clinical Pharmacology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, People’s Republic of China

    Jian Liu

Authors
  1. Linrun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiuhua Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mingzhu Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jie Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nong Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jian Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiuhua Wu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, L., Wu, X., Huang, M. et al. The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 60, 211–218 (2007). https://doi.org/10.1007/s00280-006-0363-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-006-0363-x

Keywords

Search

Navigation